Abstract
Background. To assess the contribution of IL-6 signaling to the physiopathology of Crohn’s disease, we introduced anti-IL-6 receptor monoclonal antibody to a murine colitis model. Methods. Colitis was induced in C.B-17-scid mice to which were transferred CD45RBhigh CD4+ T cells from Balb/c mice. Anti-IL-6 receptor monoclonal antibody or rat IgG was given intraperitoneally after T-cell transfer, followed by weekly injection. Vascular adhesion molecules and inducible nitric oxide synthase were visualized by immunostaining. Cytokine expression was determined by RT-PCR, and apoptotic cells were determined by the TUNEL method. Results. Mice treated with anti-IL-6 receptor monoclonal antibody showed normal growth while controls lost weight. Colitis was improved histologically with reduced infiltration of LFA-1+ monocytes/ macrophages and VLA-4+ T cells. ICAM-1 and VCAM-1 expression in the colonic vascular endothelium was markedly suppressed by the treatment, whereas no significant difference was seen in MAdCAM-1. IFN-γ, TNF-α, and IL-lβ mRNAs were markedly reduced, but no difference was observed in the expression of IL-4, IL-10, and TGF-β. Inducible nitric oxide synthase was upregulated in the mucosa of colitic mice and downregulated in the treated mice. Apoptotic cells were very sparse despite massive CD4+ T-cell infiltration in colitic mice, whereas increased apoptosis was seen in the treated mice with an apparently reduced number of T cells. Conclusions. Anti-IL-6 receptor monoclonal antibody abrogated murine colitis. It effectively blocked the expression of adhesion molecules, thereby blocking leukocyte recruitment, and increased T-cell apoptosis. These results strongly suggest the therapeutic potential of anti-IL-6 receptor monoclonal antibody for human Crohn’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997;337:1029–35.
Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521–28.
Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992;258:593–7.
Kanazawa S. Expression of IL-6 and TNF-α in Crohn’s disease intestine. Med J Osaka Univ 1998;50:33–42.
Peters M, Müller AM, Rose-John S. Interleukin-6 soluble interleukin-6 receptor: direct stimulation of gpl30 and hematopoiesis. Blood 1998;92:3495–504.
Desgeorges A, Gabay C, Silacci P, Novick D, Roux-Lombard P, Grau G, et al. Concentrations and origins of soluble interleukin-6 receptor-a in serum and synovial fluid. J Rheumatol 1997;24:1510–6.
Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995;36:45–9.
Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Thl cell-mediated murine colitis. J Immunol 2000;164:4878–82.
Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of SCID mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997;158:2099–106.
Ayroldi E, Zollo O, Cannarile L, D’Adamio F, Grohmann U, Delfino DV, et al. Interleukin-6 (IL-6) prevents activation-induced cell death: IL-2-independent inhibition of fas/fasL expression and cell death. Blood 1998;92:4212–9.
Ito H, Fathman CG. CD45RBhigh CD4+ T cells from IFN-γ knockout mice do not induce wasting disease. J Autoimmun 1997;10:455–9.
Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, et al. Transcription factor NF-IL6 and NF-kB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 1993; 90:10193–7.
Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 1998;95:8222–6.
Samoilova EB, Horton JL, Hilliard B, Liu TST, Chen Y. IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. J Immunol 1998;161:6480–6.
Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992;103:840–7.
Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315–25.
Ogawa H, Yamamoto M, Nakamura H, Ito H. Role of inducible nitric oxide synthase in murine colitis. In: Asakura H, Aoyagi Y, Nakazawa S, editors. Trends in gastroenterology and hepatology. Tokyo: Springer; 2001. p. 99–102.
Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, et al. Resistance of Crohn’s disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999;163:1081–90.
Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000;6:583–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ito, H., Hirotani, T., Yamamoto, M. et al. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn’s disease. J Gastroenterol 37 (Suppl 14), 56–61 (2002). https://doi.org/10.1007/BF03326415
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03326415